Peck Symposium 2024 Speakers
TBA, Ph.D.
Professional Title
Professional Location
Talk Title: TBA
Abstract: TBA
TBA, Ph.D.
Professional Title
Professional Location
Talk Title: TBA
Abstract: TBA
TBA, Ph.D.
Professional Title
Professional Location
Talk Title: TBA
Abstract: TBA
Niall Barron, Ph.D.
Professor of Biochemical Engineering, University College Dublin and Principal Investigator, NIBRT
Niall Barron obtained a BA(Mod) in Microbiology from Trinity College Dublin and PhD in Applied Microbiology/Biochemistry from the University of Ulster. He spent three years at Baylor College of Medicine in Houston working on genome engineering strategies to study nuclear steroid receptor function. He returned to Ireland to work on stem cell engineering at Dublin City University. His group subsequently developed a specific focus on the production of recombinant therapeutic proteins using mammalian cells. He was appointed NIBRT Principal Investigator and Professor of Biochemical Engineering in the School of Chemical and Bioprocess Engineering in UCD in 2017.
Talk Title: Modifying RNA Epigenetics to Improve the Production of Recombinant Products
Abstract: Epigenetic modifications to the nucleotides in RNA species has been generating considerable interest in recent years. The role of methylation in particular, including characterising the proteins that add (writers), remove (erasers) and interpret (readers) this epigenetic mark, will be discussed. This talk will consider the potential of targeted methylation as an enhancer of mRNA translation and how this mechanism might be applied to improving Biologics production.
Sandro Matosevic, Ph.D.
Assistant Professor of Industrial & Physical Pharmacy, Purdue University, West Lafayette IN
Dr. Matosevic’s research program focuses on developing new immunotherapies for solid tumors using translational tools to reprogram the therapeutic behavior of natural killer cells and their interaction with the tumor microenvironment by combining approaches in cell therapy, gene engineering, immunology and immunoengineering to (1) Overcome immunometabolic suppression of natural killer cell function in the tumor microenvironment via molecular modulation of their function; (2) Enhance natural killer cell anti-tumor immunity by engineering synthetic genetic constructs that can effectively target solid tumors; (3) Engineer novel cryopreservation platforms devoid of DMSO to improve patient safety upon administration of adoptive natural killer cell therapies.
Theme: Development of Cell Based Immunotherapies
Talk Title: Advances and Opportunities in the Development and Engineering of Cell-based Therapies
Abstract:
TBA, Ph.D.
Professional Title
Professional Location
Talk Title: TBA
Abstract: TBA